Uncovering the Clinical Research Propelling ILD Drug Development Forwards in 2022 & Beyond

8:30 am Registration & Networking

8:55 am Chair’s Opening Remarks

9:00 am Strategically Leveraging ILD Clinical Trials to Further Our Understanding of The Progressive Pulmonary Fibrosis Phenotype & Identify Novel Outcomes in Clinical Trials

  • Craig Conoscenti Medical Expert ILD Respiratory Clinical Development & Medical Affairs, Boehringer Ingelheim

9:30 am Looking Beyond IPF: Utilizing Lessons Learned from IPF Clinical Trials to Inform & Optimize Your ILD Trial Design & Execution

  • Eric White Senior Clinical Program Lead, Boehringer Ingelheim

10:00 am Uncovering Trial Design Considerations in Sarcoid

  • Majd Mouded Executive Director for BioMedical Research, Novartis

10:30 am Speed Networking

11:00 am Morning Break & Networking

Uncovering Emerging ILD Therapeutic Approaches

11:30 am Developing Therapies for Rare Lung Diseases: ILD 101

12:00 pm Lunch Break & Networking

1:00 pm Single vs Multiple Benefit Drugs for ILD

  • Matt Bradley Founder, Chairman, President, & Chief Technical Officer, SAJE Pharma

1:30 pm Update on Inhaled Drug Delivery: The Application of Anticalins in the Treatment of Lung Fibrosis

  • Vanessa Neins Senior Scientist - Biology Lead Respiratory, Pieris Pharmaceuticals

Analyzing & Scrutinizing ILD Mechanisms

2:00 pm Evolution of Multicellular Hubs in the Tumor Microenvironment & their Relevance for ILD Drug Development

  • Shannon Turley Vice President of Cancer Immunology Discovery, Genentech

2:30 pm The Role of Macrophage Metabolic Reprogramming During Pulmonary Fibrosis

3:00 pm Afternoon Break & Networking

Strategizing New Target Identification for Novel Therapies 101

4:00 pm Selective Inhibition of ROCK2: Promising Approach to Target Fibrosis

4:30 pm Revealing What Steps You Must Take to Successfully Identify & Validate Novel ILD Therapeutic Targets which Target Lung Epithelial injury

  • Glenn Rosen Chief Scientific Officer, Optikira & Biomotiv

5:00 pm Chair’s Closing Remarks

5:05 pm End of Conference Day Two